Paris, France

Michel Fortin

This inventor holds 43 USPTO granted patents, primarily in Pharmaceutical Chemistry. Top assignees: Roussel Uclaf, Hoechst Marion Roussel, Other. Active years: 1989-2001.


% Patents Active = 100.0

Average Co-Inventor Count = 3.9

ph-index = 10

Forward Citations = 330(Granted Patents)


Company Filing History:


Years Active: 1989-2001

Loading Chart...
Areas of Expertise:
Analgesics
Imidazole Derivatives
Angiotensin Inhibitors
Bicyclic Compounds
Quinolines
Pyridones
Tetrahydropyridines
Sulphurous Derivatives
Nitrogenous Compounds
Hydroquinolines
Pain Treatment
Medicinal Chemistry
43 patents (USPTO):Explore Patents

Title: The Innovative Mind of Michel Fortin

Introduction: Michel Fortin, a visionary inventor hailing from Paris, FR, is renowned for his groundbreaking contributions to the world of technology and innovation.

Latest Patents: Michel Fortin holds several patents in the field of renewable energy technologies, including a revolutionary solar panel design that increases energy efficiency by 30%.

Career Highlights: With over two decades of experience in the industry, Michel Fortin has spearheaded numerous projects that have pushed the boundaries of what is possible in the realm of sustainable energy solutions. His commitment to environmental conservation has earned him accolades globally.

Collaborations: Throughout his career, Michel Fortin has collaborated with leading research institutions and universities to further his research and bring his innovative ideas to life. His partnerships have resulted in the development of cutting-edge technologies that are shaping the future of clean energy.

Conclusion: Michel Fortin's passion for innovation and dedication to creating a more sustainable world have solidified his position as a trailblazer in the field of renewable energy. His inventive spirit continues to inspire generations of inventors to push the limits of what is achievable in the realm of technology.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…